The FDA has just made it easier for Sweden’s Calliditas to develop Nefecon for a rare kidney disease, accepting a faster readout that should hasten development of the drug.
Sobi has narrowed its focus to haematology and immunology, shedding staff and R&D projects in other areas whilst taking full control of a drug it licenses from Novimmune.